Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity ...

New breast cancer drug wins FDA approval after slashing progression risk by nearly 40%

The FDA-approved Inluriyo, an oral estrogen receptor antagonist from Eli Lilly, has shown to achieve significant improvement ...

Where Will LLY Be in 5 Years?

After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030.

Eli Lilly: Beyond Weight Loss

Eli Lilly ( LLY 1.32%) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand for Mounjaro (tirzepatide approved to treat type 2 diabetes) and Zepbound ...

Why Eli Lilly Is The Lion's Share Of My Portfolio

Eli Lilly’s new GLP-1 drug and diversified R&D pipeline could drive healthcare sector inflows and deliver over 40% upside.